|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/05/20 Core Laboratories NV 8-K:5,9 3/01/20 11:180K ActiveDisclosure/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 36K 2: EX-10.1 Material Contract HTML 13K 9: R1 Document And Entity Information HTML 49K 6: XML IDEA XML File -- Filing Summary XML 11K 11: XML XBRL Instance -- clb-8k_20200301_htm XML 14K 8: EXCEL IDEA Workbook of Financial Reports XLSX 6K 4: EX-101.LAB XBRL Labels -- clb-20200301_lab XML 58K 5: EX-101.PRE XBRL Presentations -- clb-20200301_pre XML 35K 3: EX-101.SCH XBRL Schema -- clb-20200301 XSD 19K 10: JSON XBRL Instance as JSON Data -- MetaLinks 12± 19K 7: ZIP XBRL Zipped Folder -- 0001564590-20-008962-xbrl Zip 11K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i March 1, 2020
CORE LABORATORIES N.V.
(Exact name of registrant as specified in its charter)
|
The i Netherlands |
Not Applicable |
|
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
i Strawinskylaan 913 |
|
Not Applicable |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: ( i 31-20) i 420-3191
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
i ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
i ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
i ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
i ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
i Common Stock (Par Value EUR 0.02) |
|
i CLB |
|
i New York Stock Exchange |
|
Common Stock (Par Value EUR 0.02) |
|
CLB |
|
Euronext Amsterdam Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On March 1, 2020, Core Laboratories N.V. (the “Company”) entered into an amendment to the March 1, 2019 Employment Agreement, by and between the Company and President and Chief Operating Officer, Mr. Lawrence V. Bruno (the “Amendment”). The Amendment increases Mr. Bruno’s maximum annual bonus from 180% to 200% of his annual base salary.
The description above of the Amendment is qualified in its entirety by reference to the Amendment, which is attached hereto as Exhibit 10.1, and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits
|
|
(d) |
|
Exhibits
|
10.1Amendment to Employment Agreement, by and between Core Laboratories N.V. and Lawrence V.
Bruno, dated March 1, 2020.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
CORE LABORATORIES N.V.
EXHIBIT INDEX TO FORM 8-K
|
|
|
|
|
EXHIBIT NO. |
|
ITEM |
|
|
|
|
|
10.1 |
|
* |
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Core Laboratories N.V. |
||||
|
|
|
|
|
|
|
|
|
Dated: March 5, 2020 |
|
By |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief Financial Officer |
|
|
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/5/20 | |||
| For Period end: | 3/1/20 | 4 | ||
| 3/1/19 | 4, 8-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/15/24 Core Laboratories Inc./DE 10-K 12/31/23 122:16M Donnelley … Solutions/FA 2/27/23 Core Laboratories Inc./DE S-4/A 1:1.9M Donnelley … Solutions/FA 2/22/23 Core Laboratories Inc./DE S-4/A 7:1.4M Donnelley … Solutions/FA 2/10/23 Core Laboratories NV 10-K 12/31/22 125:20M Donnelley … Solutions/FA 1/17/23 Core Laboratories Inc./DE S-4 9:1.5M Donnelley … Solutions/FA 6/09/22 Core Laboratories NV 424B5 2:440K Donnelley … Solutions/FA 2/10/22 Core Laboratories NV 10-K 12/31/21 124:18M Donnelley … Solutions/FA 2/08/21 Core Laboratories NV 10-K 12/31/20 128:20M ActiveDisclosure/FA 12/17/20 Core Laboratories NV 424B5 1:330K Donnelley … Solutions/FA 8/13/20 Core Laboratories NV S-3ASR 8/13/20 3:320K Donnelley … Solutions/FA |